DINA TEBCHERANY, MD
Medical Oncology Physician · AUSTIN, TX
Individual Active NPI 1578501664
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 507 | 258,865 | $21,517,757 | $6,211,200 | $4,954,148 |
| 2023 | 535 | 288,811 | $20,814,762 | $5,728,766 | $4,568,098 |
| 2022 | 560 | 324,171 | $22,568,114 | $6,443,347 | $5,150,472 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 31,900 | $56 | $44 |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 14,790 | $0 | $0 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 14,400 | $0 | $0 |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 14,385 | $3 | $2 |
| J9299 | Injection, nivolumab, 1 mg | 14,320 | $31 | $25 |
| J1756 | Injection, iron sucrose, 1 mg | 14,200 | $0 | $0 |
| J9267 | Injection, paclitaxel, 1 mg | 12,828 | $0 | $0 |
| J1453 | Injection, fosaprepitant, 1 mg | 9,600 | $0 | $0 |
| J0897 | Injection, denosumab, 1 mg | 6,900 | $25 | $20 |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 3,860 | $46 | $37 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 3,618 | $0 | $0 |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 3,162 | $20 | $16 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Medical Oncology Physician | 207RX0202X | ✓ | L3159 | TX |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Medical Oncology Physician providers in Texas
- NPI 1447414776
- NPI 1437400702
- NPI 1205079373
- NPI 1700909744
- NPI 1487818811
- NPI 1073000766
- NPI 1174686364
- NPI 1982642914
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.